Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
Metrics to compare | KURN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKURNPeersSector | |
---|---|---|---|---|
P/E Ratio | −318.9x | −3.2x | −0.5x | |
PEG Ratio | −4.32 | −0.04 | 0.00 | |
Price/Book | 20.2x | 1.0x | 2.6x | |
Price / LTM Sales | 15.7x | 5.8x | 3.2x | |
Upside (Analyst Target) | - | 99.2% | 41.6% | |
Fair Value Upside | Unlock | 0.2% | 6.0% | Unlock |